ArticleNutrients2023
2'-Fucosyllactose and 3-Fucosyllactose Alleviates Interleukin-6-Induced Barrier Dysfunction and Dextran Sodium Sulfate-Induced Colitis by Improving Intestinal Barrier Function and Modulating the Intestinal Microbiome.
Article in Nutrients, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of Human Milk Oligosaccharide 2'-Fucosyllactose Ingestion on Weight Loss and Markers of Health.Nutrients · 2024Trial
- A Comprehensive Review of Fucosylated Human Milk Oligosaccharides: Biological Functions, Production Technologies, and Safety Regulation With Commercial Translation in Infant Nutrition.Comprehensive reviews in food science and food safety · 2026Review
- Intestinal Fucosylation: A Key Regulatory Hub in Homeostasis and Disease Pathogenesis.Biomolecules · 2026Review
- 2'-FL's Depiction of the Human Physiological Function Landscape.Food science & nutrition · 2026Review
- Ulcerative colitis: signaling pathways, therapeutic targets and interventional strategies.Signal transduction and targeted therapy · 2026Review
- Microbiota-Derived Regulation of AhR and VDR Signaling in Intestinal Inflammation: Protective Roles of Prebiotics, Probiotics, and Postbiotics.International journal of molecular sciences · 2026Review
- Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.Frontiers in immunology · 2026Review
- Gastrointestinal Journey of Human Milk Oligosaccharides: From Breastfeeding Origins to Functional Roles in Adults.Microorganisms · 2025Review
- The Effect of 2'-Fucosyllactose on Gut Health in Aged Mice.Foods (Basel, Switzerland) · 2025Article
- Development and application of synthetic biology tools for improved production of human breast milk components.Synthetic and systems biotechnology · 2025Review
- "Microbial and immune modulation by 2'-fucosyllactose supplementation during gestation: a strategy to prevent food allergies".Gut microbes · 2025Article
- Protective Effects of Human Milk Oligosaccharides (hMOs) on Analgesic, Nonsteroidal Anti-inflammatory Drugs (NSAIDs)-Induced Disruption of Gut Barrier Integrity in Cocultures Mimicking Neuro-Gut Epithelial Cell Crosstalk.Molecular nutrition & food research · 2025Article
- A Synbiotic ofNutrients · 2025Article
- 2'-Fucosyllactose Modulates the Intestinal Immune Response to Gut Microbiota and Buffers Experimental Colitis in Mice: An Integrating Investigation of Colonic Proteomics and Gut Microbiota Analysis.Food science & nutrition · 2025Article
- Exploring the Potential Mechanism of Liupao Tea Using UPLC-Q-TOF/MS and Network Pharmacology.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Targeting AGE-RAGE Signaling Pathway with Hujin Decoction Ameliorates MAFLD in HepG2 Cells.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Bifidogenic Effect of Human Milk Oligosaccharides on Pediatric IBD Fecal Microbiota.Microorganisms · 2024Article
- Recent advances of 3-fucosyllactose in health effects and production.Archives of microbiology · 2024Review
- Hydroethanolic Extract ofAntioxidants (Basel, Switzerland) · 2024Article
- The effect of nerve cells on the intestinal barrier function and the influence of human milk oligosaccharides (hMOs) on the intestinal neuro-epithelial crosstalk.Current research in food science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Ulcerative colitis is an inflammatory bowel disease (IBD) with relapsing and remitting patterns, and it is caused by varied factors, such as the intestinal inflammation extent and duration. We examined the preventative effects of human milk oligosaccharides (HMOs) on epithelial barrier integrity and intestinal inflammation in an interleukin (IL)-6-induced cell model and dextran sodium sulfate (DSS)-induced acute mouse colitis model. HMOs including 2'-fucosyllactose (FL) and 3-FL and positive controls including fructooligosaccharide (FOS) and 5-acetylsalicylic acid (5-ASA) were orally administrated once per day to C57BL/6J mice with colitis induced by 5% DSS in the administered drinking water. 2'-FL and 3-FL did not affect the cell viability in Caco-2 cells. Meanwhile, these agents reversed IL-6-reduced intestinal barrier function in Caco-2 cells. Furthermore, 2'-FL and 3-FL reversed the body weight loss and the remarkably short colon lengths in DSS-induced acute colitis mice. Moreover, 2'-FL and 3-FL obviously protected the decreasing expression of zonula occluden-1 and occludin in colon tissue relative to the findings in the DSS-treated control group. 2'-FL and 3-FL significantly reduced IL-6 and tumor necrosis factor-α levels in serum relative to the control findings. The summary of these results shows that HMOs prevent colitis mainly by enhancing intestinal barrier function and advancing anti-inflammatory responses. Therefore, HMOs might suppress inflammatory responses and represent candidate treatments for IBD that protect intestinal integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.